IMU is a $1.6bn biotech that’s also more than halved over the last 6-months, its been a sorry tale across the sector. The business manufactures vaccines for gastric and breast cancers and we believe its recent collaboration with giant Merck & CO. is very encouraging providing a degree of confidence to accumulate into current weakness.
MM is neutral to positive IMU
Add To Hit List
